Live Breaking News & Updates on Athera Dabur Research Foundation

The drug is add-on therapy for asymptomatic and symptomatic Covid patients.
Khoday Group of Industries, a Bengaluru based company, has rolled out ViraNorm - ayurvedic immuno-modulator, which helps treat Covid-19 patients. Through the launch of ‘ViraNorm’, Khoday Group is entering the alternative medicine sector.
The drug ‘ViraNorm’ has been developed by Khoday Group in collaboration with Athera Dabur Research Foundation (DRF) LifeSciences.
According to the company, ‘ViraNorm’ has undergone Phase 3 clinical trials in the country for an ayurvedic formulation and conducted according to international standards of good clinical trials and is found to be effective in clinical trials and has been launched after subjecting it, thorough efficacy and safety studies. It helps to halt the progression of viruses in the body. So, this can be referred as an add-on therapy/medication for asymptomatic and symptomatic Covid patients. This helps in stopping the migration ....

Swamy Khoday , Khoday Group Of Industries , Khoday Group , Athera Dabur Research Foundation , World Health Organization , National Accreditation Board For Hospitals , Cellular Level Inflammation , Cell Mediated , Manu Jaggi , Chief Operating Officer , Clinical Trials , Victoria Hospital , National Accreditation Board , Vice Chairman , Managing Director , Dabur Research Foundation , Covid 19 , Ayurvedic Medicine , Ayurvedic Immuno Modulator , கோடாய் குழு , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , தேசிய அங்கீகாரம் பலகை க்கு மருத்துவமனைகள் , செல் மத்தியஸ்தம் , தலைமை இயங்குகிறது அதிகாரி , மருத்துவ சோதனைகள் , விக்டோரியா மருத்துவமனை ,